SCHEMBL6259280

SCHEMBL6259280

Nc1cc(Cl)ccc1OCC(=O)N1CCOCC1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.67
KDM4E B2RXH2 2/20 0.67
TDP1 Q9NUW8 1/20 0.67
FKBP1A P62942 4/20 0.62
HTT P42858 3/20 0.59
SMN1; SMN2 Q16637 4/20 0.57
HPGD P15428 3/20 0.57
TSHR P16473 3/20 0.57
GAA P10253 2/20 0.57
MAPT P10636 1/20 0.57
ALOX12 P18054 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
LMNA P02545 3/20 0.57
POLB P06746 1/20 0.56
RAB9A P51151 2/20 0.56
NPC1 O15118 1/20 0.55
MAPK1 P28482 1/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4387896 0.81 ALDH1A1 (0.58) ALDH1A1KDM4EFKBP1AHTTSMN1; SMN2
SCHEMBL5066426 0.81 CCR1 (0.61) ALDH1A1KDM4EHTTSMN1; SMN2HPGD
SCHEMBL12988518 0.81 FKBP1A (0.71) ALDH1A1KDM4EFKBP1ASMN1; SMN2TSHR
SCHEMBL6261713 0.81 KDM4E (0.79) ALDH1A1KDM4EFKBP1AHTTSMN1; SMN2
SCHEMBL4911164 0.79 KDM4E (0.56) ALDH1A1KDM4ETDP1FKBP1AHTT
SCHEMBL367867 0.77 TSHR (0.63) ALDH1A1KDM4EFKBP1AHTTSMN1; SMN2
SCHEMBL22633493 0.76 CPT2 (0.56) ALDH1A1KDM4EFKBP1AHTTSMN1; SMN2
SCHEMBL1294980 0.76 ALDH1A1 (0.71) ALDH1A1KDM4EFKBP1AHTTSMN1; SMN2
SCHEMBL5671909 0.76 HSD11B1 (0.56) ALDH1A1TDP1HTTSMN1; SMN2HPGD
SCHEMBL6441529 0.76 EPHX2 (0.54) ALDH1A1FKBP1AHTTSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050176733-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-08-11 US disclosed
WO-2005072733-A1 DYARYLUREA COMPOUNDS AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176733-A1 Chk-1 inhibitors CHEK1, CHEK2, CHKA ALDH1A1 3770/4885KDM4E 955/4885TDP1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.